thalidomide has been researched along with Pulmonary Consumption in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide treatment was well tolerated, without serious adverse events." | 6.68 | Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. ( Akarasewi, P; Burroughs, M; Johnson, B; Kaplan, G; Klausner, JD; Makonkawkeyoon, S; Molloy, A; Rom, W; Tramontana, JM; Utaipat, U, 1995) |
| "Thalidomide treatment was well tolerated, without serious adverse events." | 2.68 | Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. ( Akarasewi, P; Burroughs, M; Johnson, B; Kaplan, G; Klausner, JD; Makonkawkeyoon, S; Molloy, A; Rom, W; Tramontana, JM; Utaipat, U, 1995) |
| "Thalidomide-treated and untreated animals showed the same amount of M." | 1.32 | Experimental murine mycobacteriosis: evaluation of the functional activity of alveolar macrophages in thalidomide- treated mice. ( Arruda, MS; Oliveira, SM; Richini, VB; Vilani-Moreno, FR, 2004) |
| "Thalidomide treatment resulted in a significant reduction in tumor necrosis factor-alpha, interleukin 6 (IL-6) and IL-10 protein levels (blood) and mRNA expression (lungs)." | 1.30 | Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. ( Freedman, VH; Freeman, S; Kaplan, G; Laochumroonvorapong, P; Moreira, AL; Tsenova-Berkova, L; Wang, J, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, P | 1 |
| Pei, N | 1 |
| Liu, X | 1 |
| Huang, W | 1 |
| Lu, S | 1 |
| Subbian, S | 1 |
| Tsenova, L | 1 |
| O'Brien, P | 1 |
| Yang, G | 1 |
| Koo, MS | 1 |
| Peixoto, B | 1 |
| Fallows, D | 1 |
| Zeldis, JB | 1 |
| Muller, G | 1 |
| Kaplan, G | 4 |
| Guo, S | 1 |
| Zhao, J | 1 |
| Arruda, MS | 1 |
| Richini, VB | 1 |
| Oliveira, SM | 1 |
| Vilani-Moreno, FR | 1 |
| Marcus, JC | 1 |
| Cornea, P | 1 |
| Vladutiu, A | 1 |
| Marcovici, G | 1 |
| Tramontana, JM | 1 |
| Utaipat, U | 1 |
| Molloy, A | 1 |
| Akarasewi, P | 2 |
| Burroughs, M | 1 |
| Makonkawkeyoon, S | 2 |
| Johnson, B | 1 |
| Klausner, JD | 2 |
| Rom, W | 1 |
| Nakata, K | 1 |
| Kasinrerk, W | 1 |
| Corral, L | 1 |
| Dewar, RL | 1 |
| Lane, HC | 1 |
| Freedman, VH | 2 |
| Moreira, AL | 1 |
| Tsenova-Berkova, L | 1 |
| Wang, J | 1 |
| Laochumroonvorapong, P | 1 |
| Freeman, S | 1 |
| Gori, A | 1 |
| Rossi, MC | 1 |
| Trabattoni, D | 1 |
| Marchetti, G | 1 |
| Fusi, ML | 1 |
| Molteni, C | 1 |
| Clerici, M | 1 |
| Franzetti1, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00004276] | Phase 2 | 50 participants | Interventional | 1990-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thalidomide and Pulmonary Consumption
| Article | Year |
|---|---|
Immunotherapy for tuberculosis: what's the better choice?
Topics: Cytokines; Etanercept; Humans; Immunoglobulin G; Immunoglobulins, Intravenous; Immunologic Factors; | 2012 |
2 trials available for thalidomide and Pulmonary Consumption
| Article | Year |
|---|---|
Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis.
Topics: Adult; Aged; Cells, Cultured; Cytokines; Humans; Hypersensitivity, Delayed; Immunosuppressive Agents | 1995 |
The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection.
Topics: Adult; Body Weight; CD4 Lymphocyte Count; Double-Blind Method; HIV Infections; HIV-1; Humans; Immuno | 1996 |
7 other studies available for thalidomide and Pulmonary Consumption
| Article | Year |
|---|---|
Thalidomide in the treatment of human immunodeficiency virus-negative tuberculous meningitis: A case report.
Topics: Adrenal Cortex Hormones; Adult; Antitubercular Agents; Asian People; Brain; Drug Therapy, Combinatio | 2020 |
Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.
Topics: Animals; Antitubercular Agents; Blotting, Western; Colony-Forming Units Assay; Cyclic Nucleotide Pho | 2011 |
Experimental murine mycobacteriosis: evaluation of the functional activity of alveolar macrophages in thalidomide- treated mice.
Topics: Animals; Colony Count, Microbial; Immunosuppressive Agents; Lung; Macrophages, Alveolar; Male; Mice; | 2004 |
Non-teratogenicity of antituberculous drugs.
Topics: Abnormalities, Drug-Induced; Aminosalicylic Acids; Antitubercular Agents; Drug Synergism; Ethionamid | 1967 |
The immuno-suppressive effect of thalidomide in experimental tuberculosis in guinea-pigs.
Topics: Animals; Female; Guinea Pigs; Injections, Intradermal; Judgment; Male; Thalidomide; Tuberculin Test; | 1967 |
Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis.
Topics: Acute Disease; Animals; Apoptosis; Cytokines; Female; Immunosuppressive Agents; Interleukin-10; Inte | 1997 |
Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection.
Topics: HIV Infections; Humans; Thalidomide; Tuberculosis, Pulmonary; Tumor Necrosis Factor-alpha | 2000 |